Penserra Capital Management LLC Tricida, Inc. Transaction History

Penserra Capital Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$4.19 - $9.56 $4,839 - $11,041	-1,155 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$3.56 - $4.64 $35 - $46	10 Added 0.87%	1,155 $5,000
Q2 2021 Aug 12, 2021	BUY	$3.95 - $5.41 $79 - $108	20 Added 1.78%	1,145 $4,000
Q1 2021 May 13, 2021	SELL	$4.52 - $7.8 $180 - $312	-40 Reduced 3.43%	1,125 $5,000
Q4 2020 Feb 12, 2021	BUY	$4.37 - $9.46 $3,220 - $6,972	737 Added 172.2%	1,165 $8,000
Q3 2020 Nov 13, 2020	BUY	$8.56 - $26.93 $3,663 - $11,526	428 New	428 $3,000
Q4 2018 Feb 06, 2019	SELL	$23.57 - $32.33 $349,071 - $478,807	-14,810 Closed	0 $0
Q3 2018 Nov 05, 2018	BUY	$22.5 - $39.35 $333,225 - $582,773	14,810 New	14,810 $452,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.